Across TCGA pan-cancer cohorts, DEFB109B RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated DEFB109B data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher DEFB109B RNA is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB109B expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

OV, SKCM, and ESCA are the cancer types where DEFB109B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	IV	0.056	0.772	<.001	36	view →
SKCM	DFS	Tertile	All	0.317	0.623	.010	27	view →
ESCA	OS	Tertile	III,IV	0.795	0.385	.041	18	view →
PRAD	OS	Tertile	All	0.775	0.891	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: DEFB109B tumor-vs-normal RNA expression · all DEFB109B data types